Neurotherapeutics

, Volume 5, Issue 2, pp 210–225

Protection against Parkinson’s disease progression: Clinical experience

Neuroprotective Approach

Summary

Treatments with potential neuroprotective capability for Parkinson’s disease (PD) have been investigated in randomized, controlled, clinical trials and other studies since the mid-1980s. Although promising leads have arisen, no therapy has been proven to halt or slow disease progression. Several large-scale studies have highlighted progress in methodology, as well as the frustrations of translating laboratory science to practical applications. This review summarizes findings from clinical trials with several classes of compounds, including monoamine oxidase-B inhibitors (selegiline, lazabemide, rasagiline), dopaminergic drugs (ropinirole, pramipexole, levodopa), antioxidant strategies (α-tocopherol), mitochondrial energy enhancers (coenzyme Q10, creatine), antiapoptotic agents (TCH346, minocycline, CEP-1347), and antiglutamatergic compounds (riluzole). Beyond small-molecule pharmacology, gene therapy approaches, such as delivering neurotrophic substances (e.g., neurturin) by viral vector, are the next generation of treatment options.

Key Words

Parkinson’s disease neuroprotection neurodegeneration clinical trials disease modification 

References

  1. 1.
    Anderson DW, Bradbury KA, Schneider JS. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci 2006;24: 3174–3182.PubMedGoogle Scholar
  2. 2.
    Hirsch EC. How to judge animal models of Parkinson’s disease in terms of neuroprotection. J Neural Transm Suppl 2006;70: 255–260.PubMedGoogle Scholar
  3. 3.
    Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson’s disease: a systematic assessment. Neurology 2003;60: 1234–1240.PubMedGoogle Scholar
  4. 4.
    Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [Erratum in: Neurology. 2006;67:299]. Neurology 2006;66: 976–982.PubMedGoogle Scholar
  5. 5.
    Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson’s disease: an evidence-based review. Mov Disorders 2002;17 Suppl 4: S1-S166 (abstracts).Google Scholar
  6. 6.
    Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov Disorders 2005;20: 523–529.Google Scholar
  7. 7.
    Fearnley J, Lees AJ. Aging and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114: 2283–2301.PubMedGoogle Scholar
  8. 8.
    Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 1989;46: 1052–1060.Google Scholar
  9. 9.
    Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989;321: 1364–1371.Google Scholar
  10. 10.
    Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993;328: 176–183.Google Scholar
  11. 11.
    Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson’s disease. Biofactors 1999;9: 267–272.PubMedGoogle Scholar
  12. 12.
    Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001;49: 561–574.PubMedGoogle Scholar
  13. 13.
    Lipton SA, Gu Z, Nakamura T. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. Int Rev Neurobiol 2007;82: 1–27.PubMedGoogle Scholar
  14. 14.
    Deutch AY. Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson’s disease. J Neural Transm Suppl 2006;70: 67–70.PubMedGoogle Scholar
  15. 15.
    Zigmond MJ. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism Neurobiol Dis 1997;4: 247–253.Google Scholar
  16. 16.
    Fahn S, Oakes D, Shoulson I, et al.; Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004;351: 2498–2508.PubMedGoogle Scholar
  17. 17.
    Fahn S, Elton RL; Members of the UPDRS Development Committee. Unified Parkinson Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson’s disease. Vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987: 153–164.Google Scholar
  18. 18.
    Shults CW, Oakes D, Kieburtz K, et al.; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson’s disease: evidence for slowing of the functional decline. Arch Neurol 2002;59: 1541–1550.PubMedGoogle Scholar
  19. 19.
    Guimaraes P, Kieburtz K, Goetz CG, Elm JJ, Palesch YY, Huang P, Ravina B, Tanner CM, Tilley BC. Non-linearity of Parkinson’s disease progression: implications for sample size calculations in clinical trials. Clin Trials 2005;2: 509–518.PubMedGoogle Scholar
  20. 20.
    Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007;22: 41–47.PubMedGoogle Scholar
  21. 21.
    Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64: 208–215.PubMedGoogle Scholar
  22. 22.
    Marek K, Jennings D, Seibyl J. Do dopamine agonists or levodopa modify Parkinson’s disease progression? Eur J Neurol 2002;9 Suppl 3: 15–22.PubMedGoogle Scholar
  23. 23.
    Schillaci O, Pierantozzi M, Filippi L, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging 2005;32: 1452–1456.PubMedGoogle Scholar
  24. 24.
    Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson’s disease: a metabolic network approach. Lancet Neurol 2007;6: 926–932.PubMedGoogle Scholar
  25. 25.
    Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson’s disease. Brain 2007;130: 1834–1846.PubMedGoogle Scholar
  26. 26.
    Elm JJ, Goetz CG, Ravina B, et al. A responsive outcome for Parkinson’s disease neuroprotection futility studies. Ann Neurol 2005;57: 197–203.PubMedGoogle Scholar
  27. 27.
    Peterson AL, Nutt JG. Treatment of Parkinson’s disease with trophic factors. Neurotherapeutics 2008;5: 270–280.PubMedGoogle Scholar
  28. 28.
    Spencer JP, Jenner A, Butler J, et al. Evaluation of the prooxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson’s disease. Free Radic Res 1996; 24: 95–105.PubMedGoogle Scholar
  29. 29.
    Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol 2003;53 Suppl 3: S26-S38.PubMedGoogle Scholar
  30. 30.
    Heikkila RE, Terleckyj I, Sieber BA. Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP. J Neural Transm Suppl 1990;32: 217–227.PubMedGoogle Scholar
  31. 31.
    Giladi N, McDermott MP, Fahn S, et al.; the Parkinson Study Group. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001;56: 1712–1721.PubMedGoogle Scholar
  32. 32.
    Djaldetti R, Ziv I, Melamed E. The effect of deprenyl washout in patients with long-standing Parkinson’s disease. J Neural Transm 2002;109: 797–803.PubMedGoogle Scholar
  33. 33.
    LeWitt PA, Oakes D, Cui L; Parkinson Study Group. The need for levodopa as an endpoint of Parkinson’s disease progression in a clinical trial of selegiline and α-tocopherol. Mov Disord 1997; 12: 183–189.PubMedGoogle Scholar
  34. 34.
    Ward CD. Does selegiline delay progression of Parkinson’s disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994;57: 217–220.PubMedGoogle Scholar
  35. 35.
    Mäki-Ikola O, Heinonen E. Study design problems of DATATOP study analysis. Ann Neurol 1986;40: 946–948.Google Scholar
  36. 36.
    Tetrud JW, Langsten JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989;245: 519–522.PubMedGoogle Scholar
  37. 37.
    Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as a primary treatment of Parkinson’s disease. Acta Neurol Scand Suppl 1991;136: 70–72.PubMedGoogle Scholar
  38. 38.
    Pålhagen S, Heinonen EH, Hägglund J, et al.; Swedish Parkinson Study Group. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 1998;51: 520–525.PubMedGoogle Scholar
  39. 39.
    Pålhagen S, Heinonen E, Hägglund J, et al. Selegiline slows the progression of the symptoms of Parkinson’s disease. Neurology 2006;66: 1200–1206.PubMedGoogle Scholar
  40. 40.
    Larsen JP, Boas J, Erdal JE; The Norwegian-Danish Study Group. Does selegiline modify the progression of early Parkinson’s disease? Results from a five-year study Eur J Neurol 1999; 6: 539–547.Google Scholar
  41. 41.
    Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 2003;110: 509–515.PubMedGoogle Scholar
  42. 42.
    Parkinson Study Group. A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson’s disease. Arch Neurol 1994;51: 342–347.Google Scholar
  43. 43.
    LeWitt PA, Segel SA, Mistura KL, Schork MA. Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide. Clin Neuropharmacol 1993;16: 332–337.PubMedGoogle Scholar
  44. 44.
    Parkinson Study Group. Effect of lazabemide on the progression of imaging in early Parkinson disease. Ann Neurol 1996;40: 99–107.Google Scholar
  45. 45.
    Akao Y, Youdim MB, Davis BA, Naoi M, Rabey JM. Rasagiline mesylate, a new MAO B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. J Neurochem 2001;78: 727–735.PubMedGoogle Scholar
  46. 46.
    Maruyama W, Akao Y, Carrillo MC, et al. Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002; 24: 675–682.PubMedGoogle Scholar
  47. 47.
    Mandel S, Grunblatt E, Riederer P, et al. Neuroprotective strategies in Parkinson’s disease: an update on progress. CNS Drugs 2003;17: 729–762.PubMedGoogle Scholar
  48. 48.
    Youdim MB, Amit T, Bar-Am O, Weinstock M, Yogev-Falach M. Amyloid processing and signal transduction properties of anti-Parkinson-anti-Alzheimer neuroprotective drugs rasagiline and TV3326. Ann N Y Acad Sci 2003;993: 378–386.PubMedGoogle Scholar
  49. 49.
    Parkinson Study Group. A controlled trial of rasagiline in early Parkinson’s disease: the TEMPO Study. Arch Neurol 2002;59: 1937–1943.Google Scholar
  50. 50.
    Carlile GW, Chalmers-Redman RME, Tatton NA, et al. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric gluteraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 2000;57: 2–12.PubMedGoogle Scholar
  51. 51.
    Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 2006;67 Suppl 2: S24-S29.PubMedGoogle Scholar
  52. 52.
    Olanow CW, Schapira AH, LeWitt PA, et al. TCH346 as a neuroprotective drug in Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006;5: 1013–1020.PubMedGoogle Scholar
  53. 53.
    Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 2000;23: 34–44.Google Scholar
  54. 54.
    Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease. JAMA 2000;284: 1931–1938.Google Scholar
  55. 55.
    Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287: 1653–1661.Google Scholar
  56. 56.
    Whone AL, Watts RL, Stoessl AJ, et al.; REAL-PET Study Group. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54: 93–101.PubMedGoogle Scholar
  57. 57.
    Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord 2006;21: 343–353.PubMedGoogle Scholar
  58. 58.
    Feiten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer-344 rats. Neurobiol Aging 1992;13: 339–351.Google Scholar
  59. 59.
    Feiger B, Teismann P, Mierau J. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res 2000;883: 216–223.Google Scholar
  60. 60.
    Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson’s disease? Drugs Aging 2001;18: 389–396.PubMedGoogle Scholar
  61. 61.
    Hall ED, Andrus PK, Oostveen JA, et al. Neuroprotective effects of pramipexole against post-ischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Mov Disord 1996;11 Suppl 1: 191 (abstract).Google Scholar
  62. 62.
    Vu TQ, Ling ZD, Ma SY, et al. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J Neural Transm 2000;107: 159–176.PubMedGoogle Scholar
  63. 63.
    Sethi VH, Wu H, Oostveen JA. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res 1997;754: 181–186.Google Scholar
  64. 64.
    Cassarino DS, Fall CP, Smith TS, Bennett JP Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 1998;71: 295–301.PubMedGoogle Scholar
  65. 65.
    Kitamura Y, Kosaka T, Kakimura JI, et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1998;54: 1046–1054.PubMedGoogle Scholar
  66. 66.
    Zou L, Xu J, Jankovic J, He Y, Appel SH, Le W. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett 2000;281: 167–170.PubMedGoogle Scholar
  67. 67.
    Le WD, Jankovic J, Xie W, Appel SH. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 2000;107: 1165–1173.PubMedGoogle Scholar
  68. 68.
    Carvey P, Pieri S, Ling Z. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997;104: 209–228.PubMedGoogle Scholar
  69. 69.
    Ling ZD, Robie HC, Tong CW, Carvey PM. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J Pharmacol Exp Ther 1999;289: 202–210.PubMedGoogle Scholar
  70. 70.
    Anderson DW, Neavin T, Smith JA, Schneider JS. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res 2001;905: 44–53.PubMedGoogle Scholar
  71. 71.
    Abramova NA, Cassarino DS, Khan SM, Painter TW, Bennett JP Jr. Inhibition by R(+) or S(−) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res 2002;67: 494–500.PubMedGoogle Scholar
  72. 72.
    Takata K, Kitamura Y, Kakimura J, Kohno Y, Taniguchi T. Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole. Brain Res 2000;872: 236–241.PubMedGoogle Scholar
  73. 73.
    Tanaka K, Miyazaki I, Fujita N, Haque ME, Asanuma M, Ogawa N. Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist. Neurochem Res 2001;26: 31–36.PubMedGoogle Scholar
  74. 74.
    Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson’s disease. Exp Neurol 2003;184 Suppl 1: S68-S79.PubMedGoogle Scholar
  75. 75.
    Rakshi JS, Pavese N, Uema T, et al. A comparison of the progression of early Parkinson’s disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. J Neural Transm 2002; 109: 1433–1443.PubMedGoogle Scholar
  76. 76.
    LeWitt P, Aizenman E, Newcomer T, Loeffler D; Parkinson Study Group. The search for an endogenous neurotoxin in Parkinson’s disease: TOPA and TOPA-quinone. Mov Disord 1994; 9: 482 (abstract).Google Scholar
  77. 77.
    Maharaj H, Sukhdev Maharaj D, Scheepers M, Mokokong R, Daya S. L-DOPA administration enhances 6-hydroxydopamine generation. Brain Res 2005;1063: 180–186.PubMedGoogle Scholar
  78. 78.
    Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord 2004; 19: 997–1005.PubMedGoogle Scholar
  79. 79.
    Camp DM, Loeffler DA, LeWitt PA. L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion. J Neurochem 2000;74: 1229–1240.PubMedGoogle Scholar
  80. 80.
    Chan PL, Nutt JG, Holford NH. Levodopa slows progression of Parkinson’s disease: external validation by clinical trial simulation. Pharm Res 2007;24: 791–802.PubMedGoogle Scholar
  81. 81.
    Fahn S. A pilot trial of high-dose α-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 1992;32 Suppl: S128-S132.PubMedGoogle Scholar
  82. 82.
    Canet-Avilés RM, Wilson MA, Miller DW, et al. The Parkinson’s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A 2004;101: 9103–9108.PubMedGoogle Scholar
  83. 83.
    The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68: 20–28.Google Scholar
  84. 84.
    Cleren C, Yang L, Lorenzo B, et al. Therapeutic effects of Coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of parkinsonism. J Neurochem 2007 Dec 8 [Epub ahead of print].Google Scholar
  85. 85.
    Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999;157: 142–149.PubMedGoogle Scholar
  86. 86.
    Constantinescu R, McDermott MP, Dicenzo R, et al. A randomized study of the bioavailability of different formulations of coenzyme Q10 (ubiquinone). J Clin Pharmacol 2007;47: 1580–1586.PubMedGoogle Scholar
  87. 87.
    Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson’s disease. Neurology 2007;69: 1480–1490.Google Scholar
  88. 88.
    The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66: 664–671.Google Scholar
  89. 89.
    Bender A, Koch W, Elstner M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006;67: 1262–1264.PubMedGoogle Scholar
  90. 90.
    Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL. Recent clinical failures in Parkinson’s disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 2006;72: 1197–1206.PubMedGoogle Scholar
  91. 91.
    Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc Natl Acad Sci U S A 2001;98: 14669–14674.PubMedGoogle Scholar
  92. 92.
    Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002;22: 1763–1771.PubMedGoogle Scholar
  93. 93.
    He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 2001;909: 187–193.PubMedGoogle Scholar
  94. 94.
    Diguet E, Fernagut PO, Wei X, et al. Deleterious effects of minocycline in animal models of Parkinson’s disease and Huntington’s disease. Eur J Neurosci 2004;19: 3266–3276.PubMedGoogle Scholar
  95. 95.
    Ishitani R, Kimura M, Sunaga K, Katsube N, Tanaka M, Chuang DM. An antisense oligonucleotide to glyceraldehyde-3-phosphate-dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J Pharmacol Exp Ther 1996;278: 447–454.PubMedGoogle Scholar
  96. 96.
    Ishitani R, Sunaga K, Hirano A, Saunders P, Katsube N, Chuang DM. Evidence that glyceraldehyde-3-phosphate-dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J Neurochem 1996;66: 928–935.PubMedGoogle Scholar
  97. 97.
    Kragten E, Lalande I, Zimmermann K, et al. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(−)-deprenyl. J Biol Chem 1998; 273: 5821–5828.PubMedGoogle Scholar
  98. 98.
    Andringa G, Cools AR. The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson’s disease, the bilaterally MPTP-treated rhesus monkey. J Neural Transm Suppl 2000;60: 215–225.PubMedGoogle Scholar
  99. 99.
    Maroney AC, Glicksman MA, Basma AN, et al. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci 1998;18: 104–111.PubMedGoogle Scholar
  100. 100.
    Parkinson Study Group. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology 2004;62: 330–332.Google Scholar
  101. 101.
    Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613–622.PubMedGoogle Scholar
  102. 102.
    Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson’s disease. Science 2003;302: 819–822.PubMedGoogle Scholar
  103. 103.
    Rascol O, Olanow CW, Brooks D, et al. A 2-year multicenter placebo-controlled, double blind parallel group study of the effect of riluzole in Parkinson’s disease. Mov Disord 2002;17 (Suppl 5): 39 (abstract).Google Scholar
  104. 104.
    Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson’s disease. Parkinsonism Relat Disord 2002;8: 271–276.PubMedGoogle Scholar
  105. 105.
    Vatassery GT, Fahn S, Kuskowski MA; Parkinson Study Group. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Neurology 1998;50: 1900–1902.PubMedGoogle Scholar
  106. 106.
    Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson’s disease. Arch Neurol 1995;52: 237–245.Google Scholar
  107. 107.
    Carlsson T, Björklund T, Kirik D. Restoration of the striatal dopamine synthesis for Parkinson’s disease: viral vector-mediated enzyme replacement strategy. Curr Gene Ther 2007;7: 109–120.PubMedGoogle Scholar
  108. 108.
    Herzog CD, Dass B, Holden JE, et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 2007;22: 1124–1132.PubMedGoogle Scholar
  109. 109.
    Gasmi M, Herzog CD, Brandon EP, et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson’s disease. Mol Ther 2007;15: 62–68.PubMedGoogle Scholar
  110. 110.
    Xue YQ, Zhao LR, Guo WP, Duan WM. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson’s disease. Neuroscience 2007;146: 1245–1258.PubMedGoogle Scholar
  111. 111.
    Yamada M, Mizuno Y, Mochizuki H. Parkin gene therapy for α-synucleinopathy: a rat model of Parkinson’s disease [Erratum in: Hum Gene Ther 2005;16:400]. Hum Gene Ther 2005; 16: 262–270.PubMedGoogle Scholar
  112. 112.
    Mochizuki H. Gene therapy for Parkinson’s disease. Expert Rev Neurother 2007;7: 957–960.PubMedGoogle Scholar
  113. 113.
    Ren Y, Liu W, Jiang H, Jiang Q, Feng J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J Biol Chem 2005;280: 34105–34112.PubMedGoogle Scholar
  114. 114.
    Hunter RL, Dragicevic N, Seifert K, et al. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 2007;100: 1375–1386.PubMedGoogle Scholar
  115. 115.
    Chen H, Zhang SM, Hemán MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60: 1059–1064.PubMedGoogle Scholar
  116. 116.
    Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease. Proc Natl Acad Sci U S A 2004;101: 9435–9440.PubMedGoogle Scholar
  117. 117.
    Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson’s disease. J Neurochem 2002;80: 262–270.PubMedGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2008

Authors and Affiliations

  1. 1.Department of NeurologyHenry Ford HospitalDetroit
  2. 2.Department of NeurologyWayne State University School of MedicineDetroit
  3. 3.Department of Neurology and OphthalmologyMichigan State University School of Osteopathic MedicineEast Lansing
  4. 4.Henry Ford Health Systems-Franklin Pointe Medical CenterSouthfield

Personalised recommendations